Protein / target
Serine/threonine-protein kinase B-raf
Protein at a glance
Biological role
Protein serine/threonine kinase activity
Primary system
Nervous system
Strongest disease association
cardiofaciocutaneous syndrome
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
8 approved · 10 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)
Subcellular location
Domains and Gene Ontology detail (33)Hide
Domains & features
Gene Ontology
- Ccell body
- Ccytoplasm
- Ccytosol
- Cglutamatergic synapse
- Cmitochondrion
- Cneuron projection
- Cnucleus
- Cplasma membrane
- Cpostsynapse
- FATP binding
- Fcalcium ion binding
- Fidentical protein binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Kinase signalling
- ·Protein kinase involved in the transduction of mitogenic signals from the cell membrane…
- ·MAP kinase kinase activity
- ·MAP kinase kinase kinase activity
- ·protein kinase activity
Synaptic signalling
- ·Protein kinase involved in the transduction of mitogenic signals from the cell membrane…
- ·glutamatergic synapse
- ·postsynapse
- ·postsynaptic modulation of chemical synaptic transmission
Excitatory neurotransmission
- ·glutamatergic synapse
Transcriptional regulation
- ·positive regulation of gene expression
Apoptosis & cell death
- ·negative regulation of apoptotic process
View underlying pathways (16)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Serine/threonine-protein kinase B-raf inhibitor
Appears in clinical studies involving melanoma, colorectal neoplasm, neoplasm, metastatic melanoma
Serine/threonine-protein kinase B-raf inhibitor
Appears in clinical studies involving melanoma, metastatic melanoma, melanoma, neoplasm
Serine/threonine-protein kinase B-raf inhibitor
Appears in clinical studies involving colorectal cancer, metastatic colorectal cancer, colorectal neoplasm, neoplasm
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 3,139 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 18 total
central nervous system neoplasm · central nervous system cancer · melanoma
melanoma · thyroid cancer · neoplasm
renal cell carcinoma · hepatocellular carcinoma · renal cell carcinoma
colorectal cancer · metastatic colorectal cancer · colorectal neoplasm
glioma · low grade glioma · low grade glioma
metastatic melanoma · melanoma · low grade glioma
colorectal cancer · melanoma
melanoma · glioma · neoplasm
melanoma · thyroid cancer
endometrial cancer · thyroid cancer · thyroid gland papillary carcinoma
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 3 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- New publicationEncorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i>-Mutated Colorectal Cancer.
- New publicationEncorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
- New publicationEfficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes.
- New publicationMolecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.
- New publicationEfficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.
- New publicationLenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
- New publicationTargeted therapy for hepatocellular carcinoma.
- New publicationMolecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
- New publicationEncorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
- New publicationRandomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
- Regulatory approval
Approval: Braftovi (EMA)
- New publicationEncorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.